Malignant neoplasm of endometrium
Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes
Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials
Merck’s KEYTRUDA Receives 30th European Approval for Gynecologic Cancers
KEYTRUDA, pembrolizumab, European Commission, gynecologic cancers, endometrial cancer, cervical cancer, cancer treatment, immunotherapy.
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
FDA Approves First Engineered T Cell Therapy for Solid Tumors, Expands GSK’s Jemperli
FDA approval, engineered T cell therapy, solid tumors, GSK’s Jemperli, dostarlimab-gxly, afamitresgene autoleucel, Tecelra, endometrial cancer, synovial sarcoma
GSK Secures Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
GSK, Jemperli, dostarlimab, endometrial cancer, FDA approval, chemotherapy, immuno-oncology, Keytruda, Merck
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival
FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment
FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy
AstraZeneca’s IMFINZI Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Endometrial Cancer
IMFINZI, durvalumab, endometrial cancer, mismatch repair deficient, chemotherapy, AstraZeneca, FDA approval
Keytruda Fails to Show Significant Benefit in Newly Diagnosed Endometrial Cancer Patients
Keytruda, endometrial cancer, clinical trial, newly diagnosed, immunotherapy, treatment, cancer therapy, clinical outcomes.
Evaluation of Keytruda Combined with Chemotherapy as Post-Surgical Treatment in Newly Diagnosed Endometrial Cancer Shows Limited Efficacy
Keytruda, Merck, endometrial cancer, post-surgical therapy, newly diagnosed, chemotherapy, clinical trial, limited efficacy.